Home
HelpEpic Test Code LAB21061 Supersaturation Profile, 24 Hour, Urine
Additional Codes
MML:SUP24
Ordering Guidance
Necessary Information
1. 24-Hour volume (in milliliters) is required.
2. Patient's height in centimeters and weight in kilograms are required if patient is younger than 18 years.
Specimen Required
Patient Preparation:
X-ray dyes and contrast media will affect uric acid test results.
-If a kidney X-ray with dye or computerized tomography (CT) scan with contrast has been performed, patient should wait a minimum of 1 day before starting collection.
-If a cholangiography (bile duct X-ray) has performed, patient should wait 7 days before starting collection.
-Urine must be collected before tablets have been taken for gallbladder X-ray, otherwise patient should wait 7 days before starting collection.
Supplies: Diazolidinyl Urea (Germall) 5.0 mL (T822)
Collection Container/Tube: 24-hour graduated urine container with no metal cap or glued insert
Submission Container/Tube: Plastic, 60-mL urine bottle
Specimen Volume: 35 mL
Collection Instructions:
1. Add 5 mL of diazolidinyl urea as preservative at start of collection or refrigerate specimen during and after collection.
2. Collect urine for 24 hours.
3. Specimen pH should be between 4.5 and 8 and will stay in this range if diazolidinyl urea is added at the beginning of the collection or kept refrigerated during the entirety of the collection. Specimens with pH above 8 indicate bacterial contamination, and testing will be canceled. Do not attempt to adjust pH as it will adversely affect results.
4. If not using Germall, the specimen must be kept refrigerated during the entirety of the collection and sent frozen.
Additional Information: See Urine Preservatives-Collection and Transportation for 24-Hour Urine Specimens for multiple collections.
Useful For
Diagnosis and management of patients with renal lithiasis:
-Predicting the likely composition of the stone, in patients who have a radiopaque stone, for whom stone analysis is not available
-May aid in designing a treatment program
Aiding in identification of specific risk factors for stones using a 24-hour urine collection
Monitoring the effectiveness of therapy by confirming that the crystallization potential has indeed decreased
Evaluating kidney excretion of acid and urine pH
Estimating a patient's protein intake
Profile Information
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| SSINT | Supersaturation, 24 HR, U 1 | No | Yes |
| NAUT | Sodium, 24 HR, U | Yes, (order NAU) | Yes |
| KUT | Potassium, 24 HR, U | Yes, (order KUR) | Yes |
| CALUT | Calcium, 24 HR, U | Yes, (order CALU) | Yes |
| MAGT | Magnesium, 24 HR, U | Yes, (order MAGU) | Yes |
| CLUT | Chloride, 24 HR, U | Yes, (order CLU) | Yes |
| POUT | Phosphorus, 24 HR, U | Yes, (order POU) | Yes |
| SULFT | Sulfate, 24 HR, U | Yes, (order SULFU) | Yes |
| CITT | Citrate Excretion, 24 HR, U | Yes, (order CITR) | Yes |
| OXUT | Oxalate, 24 HR, U | Yes, (order OXU) | Yes |
| UPHT | pH, 24 HR, U | Yes, (order PHU_) | Yes |
| URICT | Uric Acid, 24 HR, U | Yes, (order URCU) | Yes |
| CTUT | Creatinine, 24 HR, U | Yes, (order URCU) | Yes |
| OSMUT | Osmolality, 24 HR, U | Yes, (order UOSMU) | Yes |
| AMMT | Ammonium, 24 HR, U | Yes, (order AMMO) | Yes |
| UNT | Urea Nitrogen, 24 HR, U | No | Yes |
| PCRUT | Protein Catabolic Rate, 24 HR, U | No | Yes |
| DEMO9 | Patient Demographics | No | Yes |
Special Instructions
Method Name
AMMT, CITT, OXUT: Enzymatic
OSMUT: Freezing Point Depression
SULFT: High-Performance Ion Chromatography (HPIC)
CALUT, POUT: Photometric
MAGT: Colorimetric Endpoint Assay
UPHT: pH Meter
NAUT, KUT, CLUT: Potentiometric, Indirect Ion-Selective Electrode (ISE)
CTUT: Enzymatic Colorimetric Assay
URICT: Uricase
UNT: Kinetic UV Assay
PCRUT, SSINT: Calculation
Reporting Name
Supersaturation, 24 HR, USpecimen Type
UrineSpecimen Minimum Volume
25 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Urine | Refrigerated (preferred) | 14 days | |
| Frozen | 14 days | ||
| Ambient | 72 hours |
Clinical Information
Urine is often supersaturated, which favors precipitation of several crystalline phases, such as calcium oxalate, calcium phosphate, and uric acid. However, crystals do not always form in supersaturated urine because supersaturation is balanced by crystallization inhibitors that are present in the urine. Urinary inhibitors include ions (eg, citrate) and macromolecules but remain poorly understood.
Urine supersaturation is calculated by measuring the concentration of all the ions that can interact (potassium, calcium, phosphorus, oxalate, uric acid, citrate, magnesium, sodium, chloride, sulfate, and pH). Once the concentrations of all the relevant urinary ions are known, a computer program can calculate the theoretical supersaturation with respect to the important crystalline phases (eg, calcium oxalate).(1)
Since the supersaturation of urine has been shown to correlate with stone type,(2) therapy is often targeted towards decreasing the urinary supersaturations identified. Treatment strategies include alterations in diet and fluid intake as well as drug therapy; all designed to decrease the urine supersaturation.
Reference Values
SUPERSATURATION REFERENCE MEANS (Delta G: DG)
Men:
Calcium oxalate: 1.89 DG
Brushite: 0.46 DG
Hydroxyapatite: 4.19 DG
Uric acid: 1.18 DG
Women:
Calcium oxalate: 1.59 DG
Brushite: -0.11 DG
Hydroxyapatite: 3.62 DG
Uric acid: 0.89 DG
INDIVIDUAL URINE ANALYTES
OSMOLALITY, 24 HOUR, URINE
0-11 months: 50-750 mOsm/kg
≥12 months: 150-1,150 mOsm/kg
pH, 24 HOUR, URINE
4.5-8.0
SODIUM, 24 HOUR, URINE
≥18 years: 22-328 mmol/24 h
Reference values have not been established for patients who are younger than 18 years.
POTASSIUM, 24 HOUR, URINE
≥18 years: 16-105 mmol/24 h
Reference values have not been established for patients who are younger than 18 years.
CALCIUM, 24 HOUR, URINE
Males: <250 mg/24 h
Females: <200 mg/24 h
Reference values have not been established for patients who are younger than 18 years.
MAGNESIUM, 24 HOUR, URINE
51-269 mg/24 h
Reference values have not been established for patients who are younger than 18 years.
CHLORIDE, 24 HOUR, URINE
≥18 years: 34-286 mmol/24 h
Reference values have not been established for patients who are younger than 18 years.
PHOSPHORUS, 24 HOUR, URINE
≥18 years: 226-1,797 mg/24 h
Reference values have not been established for patients who are younger than 18 years.
SULFATE, 24 HOUR, URINE
7-47 mmol/24 h
CITRATE EXCRETION, 24 HOUR, URINE
0-19 years: Not established
20 years: 150-1,191 mg/24 h
21 years: 157-1,191 mg/24 h
22 years: 164-1,191 mg/24 h
23 years: 171-1,191 mg/24 h
24 years: 178-1,191 mg/24 h
25 years: 186-1,191 mg/24 h
26 years: 193-1,191 mg/24 h
27 years: 200-1,191 mg/24 h
28 years: 207-1,191 mg/24 h
29 years: 214-1,191 mg/24 h
30 years: 221-1,191 mg/24 h
31 years: 228-1,191 mg/24 h
32 years: 235-1,191 mg/24 h
33 years: 242-1,191 mg/24 h
34 years: 250-1,191 mg/24 h
35 years: 257-1,191 mg/24 h
36 years: 264-1,191 mg/24 h
37 years: 271-1,191 mg/24 h
38 years: 278-1,191 mg/24 h
39 years: 285-1,191 mg/24 h
40 years: 292-1,191 mg/24 h
41 years: 299-1,191 mg/24 h
42 years: 306-1,191 mg/24 h
43 years: 314-1,191 mg/24 h
44 years: 321-1,191 mg/24 h
45 years: 328-1,191 mg/24 h
46 years: 335-1,191 mg/24 h
47 years: 342-1,191 mg/24 h
48 years: 349-1,191 mg/24 h
49 years: 356-1,191 mg/24 h
50 years: 363-1,191 mg/24 h
51 years: 370-1,191 mg/24 h
52 years: 378-1,191 mg/24 h
53 years: 385-1,191 mg/24 h
54 years: 392-1,191 mg/24 h
55 years: 399-1,191 mg/24 h
56 years: 406-1,191 mg/24 h
57 years: 413-1,191 mg/24 h
58 years: 420-1,191 mg/24 h
59 years: 427-1,191 mg/24 h
60 years: 434-1,191 mg/24 h
>60 years: Not established
OXALATE, 24 HOUR, URINE
0.11-0.46 mmol/24 h
9.7-40.5 mg/24 h
Reference values have not been established for patients who are younger than 16 years.
URIC ACID, 24 HOUR, URINE
Males: ≥18 years: 200-1,000 mg/24 h
Females: ≥18 years: 250-750 mg/24 h
Reference values have not been established for patients who are younger than 18 years.
CREATININE, 24 HOUR, URINE
Males: ≥18 years: 930-2,955 mg/24 h
Females: ≥18 years: 603-1,783 mg/24 h
Reference values have not been established for patients who are younger than 18 years.
AMMONIUM, 24 HOUR, URINE
15-56 mmol/24 h
Reference values have not been established for patients who are younger than 18 years or older than 77 years.
UREA NITROGEN, 24 HOUR, URINE
≥18 years: 7-42 g/24 h
Reference values have not been established for patients who are younger than 18 years.
PROTEIN CATABOLIC RATE, 24 HOUR, URINE
56-125 g/24 h
Interpretation
Delta G (DG), the Gibbs free energy of transfer from a supersaturated to a saturated solution, is negative for undersaturated solutions and positive for supersaturated solutions. In most cases, the supersaturation levels are slightly positive, even in normal individuals, but are balanced by an inhibitor activity.
While the DG of urine is often positive, even in the urine of non-stone formers, on average, the DG is more positive in those individuals who do form kidney stones. The reference values were derived by comparing urinary DG values for the important stone-forming crystalline phases between a population of stone formers and a population of non-stone formers. DG values that are outside the expected range in a population of non-stone formers are marked abnormal.
If the urine citrate is low, secondary causes should be excluded, including hypokalemia, renal tubular acidosis, gastrointestinal bicarbonate losses (eg, diarrhea or malabsorption), or an exogenous acid load (eg, excessive consumption of meat protein).
A normal or increased citrate value suggests that potassium citrate may be a less effective choice for treatment of a patient with calcium oxalate or calcium phosphate stones.
An increased urinary oxalate value may prompt a search for genetic abnormalities of oxalate production (ie, primary hyperoxaluria). Secondary hyperoxaluria can result from diverse gastrointestinal disorders that result in malabsorption. Milder hyperoxaluria could result from excess dietary oxalate consumption or reduced calcium (dairy) intake, perhaps even in the absence of gastrointestinal disease.
High urine ammonium and low urinary pH suggest ongoing gastrointestinal losses. Such patients are at risk of uric acid and calcium oxalate stones.
Low urine ammonium and high urine pH suggest renal tubular acidosis. Such patients are at risk of calcium phosphate stones.
Patients with calcium oxalate and calcium phosphate stones are often treated with citrate to raise the urine citrate (a natural inhibitor of calcium oxalate and calcium phosphate crystal growth). However, since citrate is metabolized to bicarbonate (a base), this drug can also increase the urine pH. If the urine pH gets too high with citrate treatment, one may unintentionally increase the risk of calcium phosphate stones. Monitoring the urine ammonium concentration is one way to titrate the citrate dose and avoid this problem. A good starting citrate dose is about one-half of the urine ammonium excretion (in mEq of each). One can monitor the effect of this dose on urine ammonium, citrate, and pH values and adjust the citrate dose based on the response. A fall in urine ammonium levels should indicate whether the current citrate is enough to partially (but not completely) counteract the daily acid load of that given patient.
The protein catabolic rate is calculated from urine urea. Under routine conditions, the required protein intake is often estimated as 0.8 g/ kg body weight.
The results can be used to determine the likely effect of a therapeutic intervention on stone-forming risk. For example, taking oral potassium citrate will raise the urinary citrate excretion, which should reduce calcium phosphate supersaturation (by reducing free ionic calcium), but citrate administration also increases urinary pH (because it represents an alkali load), which promotes calcium phosphate crystallization. The net result of this or any therapeutic manipulation could be assessed by collecting a 24-hour urine and comparing the supersaturation calculation for calcium phosphate before and after therapy.
Important stone-specific factors:
-Calcium oxalate stones: urine volume, calcium, oxalate, citrate, and uric acid excretion are all risk factors that are possible targets for therapeutic intervention.
-Calcium phosphate stones (apatite or brushite): urinary volume, calcium, pH, and citrate significantly influence the supersaturation of calcium phosphate. Of note, a urine pH below 6 may help reduce the tendency for these stones to form.
-Uric acid stones: urine pH, volume, and uric acid excretion levels influence the supersaturation. Urine pH is especially critical, in that uric acid is unlikely to crystallize if the pH is above 6.
-Sodium urate stones: alkaline pH and high uric acid excretion promote stone formation.
A low urine volume is a universal risk factor for all types of kidney stones.
Cautions
Urine is often supersaturated with respect to the common crystalline constituents of stones, even in non-stone formers.
Individual interpretation of the supersaturation values in light of the clinical situation is critical. In particular, treatment may reduce the supersaturation with respect to one crystal type but increase the supersaturation with respect to another. Therefore, the specific goals of treatment must be considered when interpreting the test results.
Day(s) Performed
Monday through Sunday
Report Available
2 to 5 daysSpecimen Retention Time
See Individual Test IDsPerforming Laboratory
Mayo Clinic Laboratories in Rochester
CPT Code Information
82340-Calcium
82436-Chloride
82507-Citrate excretion
82570-Creatinine
83735-Magnesium
83935-Osmolality
83945-Oxalate
83986-pH
84105-Phosphorus
84133-Potassium
84300-Sodium
84392-Sulfate
84560-Uric acid
82140-Ammonium
84540-Urea Nitrogen
NY State Approved
YesForms
If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.